Adriamycin pfs and Tooth resorption - a phase IV clinical study of FDA data

Summary:

Tooth resorption is reported as a side effect among people who take Adriamycin pfs (doxorubicin hydrochloride), especially for people who are female, 40-49 old, also take Aredia, and have Breast cancer.

The phase IV clinical study analyzes which people have Tooth resorption when taking Adriamycin pfs. It is created by eHealthMe based on reports of 6,484 people who have side effects when taking Adriamycin pfs from the FDA, and is updated regularly.

What is Adriamycin pfs?

Adriamycin pfs has active ingredients of doxorubicin hydrochloride. eHealthMe is studying from 6,495 Adriamycin pfs users. Check the latest studies of Adriamycin pfs.

What is Tooth resorption?

Tooth resorption (the breakdown or destruction, and subsequent loss, of the root structure of a tooth) is found to be associated with 42 drugs and 89 conditions by eHealthMe. Check the latest studies of Tooth resorption.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

6,484 people reported to have side effects when taking Adriamycin pfs.
Among them, 17 people (0.26%) have Tooth resorption.

Could Adriamycin pfs cause Tooth resorption?

Among these 17 people:

What is the gender of people who have Tooth resorption when taking Adriamycin pfs? *

female: 100 %
male: 0.0 %

What is the age of people who have Tooth resorption when taking Adriamycin pfs? *

What are other drugs people take besides Adriamycin pfs? *

What are other side effects people have besides Tooth resorption? *

Wound Dehiscence (a surgical incision reopens either internally or externally): 17 people, 100.00%
Impaired Healing: 17 people, 100.00%
Nodule (a growth of abnormal tissue): 17 people, 100.00%
Nasal Mucosal Disorder (disease of mucous membrane): 17 people, 100.00%
Mucosal Erosion (peeling off of mucous membrane): 17 people, 100.00%
Mouth Haemorrhage (bleeding from mouth): 17 people, 100.00%
Macroglossia (large tongue): 17 people, 100.00%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 17 people, 100.00%
Jaw Disorder (jaw disease): 17 people, 100.00%
Injury: 17 people, 100.00%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 17 people, 100.00%
Breast Cancer: 17 people, 100.00%
Metastases To Bone (cancer spreads to bone): 14 people, 82.35%
Bone Disorder: 3 people, 17.65%

* Approximation only. Some reports may have incomplete information.

Do you take Adriamycin pfs and have Tooth resorption?

- Check whether Tooth resorption is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adriamycin pfs:

Adriamycin pfs (6,495 reports)

Browse all side effects of Adriamycin pfs:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tooth resorption:

Tooth resorption (42 drugs)

Browse all the conditions that are associated with Tooth resorption:

Tooth resorption (89 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on doxorubicin hydrochloride (the active ingredients of Adriamycin pfs) and Adriamycin pfs (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.